[Therapeutic innovations in gastroesophageal reflux].

Abstract

Proton-pump inhibitors remain the most effective treatment for relieving symptoms, healing lesions and preventing recurrences of gastroesophageal reflux (GER). Drugs inhibiting transient relaxation of the lower esophageal sphincter have an unfavorable benefit/risk ratio. Endoscopic methods developed in recent years have not been shown effective in trials versus sham procedures. Surgical treatment is effective in GER but causes frequent uncomfortable side effects that are difficult to treat.

• Authors: Marc-André Bigard
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 36 Issue 12 Pt 3 Pg. 1907-12 (Dec 2007) ISSN: 0755-4982 [Print] France
• Vernacular Title: Nouveautés thérapeutiques dans le reflux gastro-oesophagien.
• PMID: 17531431 (Publication Type: Comparative Study, English Abstract, Journal Article, Review)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• AZD0865
• Anti-Ulcer Agents
• Enzyme Inhibitors
• Gastrointestinal Agents
• Imidazoles
• Proton Pump Inhibitors
• Pyridines
• Lansoprazole
• Omeprazole
• Cisapride

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (administration & dosage, therapeutic use)
• Adult
• Anti-Ulcer Agents (administration & dosage, therapeutic use)
• Catheter Ablation
• Cisapride (administration & dosage, therapeutic use)
• Endoscopy
• Enzyme Inhibitors (administration & dosage, therapeutic use)
• Fundoplication
• Gastroesophageal Reflux (drug therapy, physiopathology, surgery, therapy)
• Gastrointestinal Agents (administration & dosage, therapeutic use)
• Humans
• Imidazoles (administration & dosage, therapeutic use)
• Lansoprazole
• Laparotomy
• Omeprazole (administration & dosage, therapeutic use)
• Proton Pump Inhibitors
• Pyridines (administration & dosage, therapeutic use)
• Quality of Life
• Randomized Controlled Trials as Topic
• Risk Assessment
• Secondary Prevention
• Time Factors